Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacokinetics of telithromycin in plasma and soft tissues after single-dose administration to healthy volunteers.

Literature DB >> 15561839

Pharmacokinetics of telithromycin in plasma and soft tissues after single-dose administration to healthy volunteers.

Rainer Gattringer¹, Eleonora Urbauer, Friederike Traunmüller, Markus Zeitlinger, Pejman Dehghanyar, Petra Zeleny, Wolfgang Graninger, Markus Müller, Christian Joukhadar.

Abstract

By use of microdialysis we assessed the concentrations of telithromycin in muscle and adipose tissue to test its ability to penetrate soft tissues. The ratios of the area under the concentration-versus-time curve from 0 to 24 h to the MIC indicated that free concentrations of telithromycin in tissue and plasma might be effective against Streptococcus pyogenes but not against staphylococci and human and animal bite pathogens.

Entities: Chemical Species

Mesh：

Substances：

Year: 2004 PMID： 15561839 PMCID： PMC529224 DOI： 10.1128/AAC.48.12.4650-4653.2004

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

21 in total

1. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.

Authors: P H Edelstein; M A Edelstein
Journal: Antimicrob Agents Chemother Date: 1999-01 Impact factor: 5.191

2. Telithromycin.

Authors: J A Balfour; D P Figgitt
Journal: Drugs Date: 2001 Impact factor: 9.546

Review 3. Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin.

Authors: G Drusano
Journal: Clin Microbiol Infect Date: 2001 Impact factor: 8.067

4. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients.

Authors: G M Joynt; J Lipman; C D Gomersall; R J Young; E L Wong; T Gin
Journal: J Antimicrob Chemother Date: 2001-04 Impact factor: 5.790

Review 5. Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens.

Authors: D Felmingham; G Zhanel; D Hoban
Journal: J Antimicrob Chemother Date: 2001-09 Impact factor: 5.790

Review 6. Microdialysis. A novel tool for clinical studies of anti-infective agents.

Authors: C Joukhadar; H Derendorf; M Müller
Journal: Eur J Clin Pharmacol Date: 2001-06 Impact factor: 2.953

7. Effect of telithromycin (HMR 3647) on polymorphonuclear neutrophil killing of Staphylococcus aureus in comparison with roxithromycin.

Authors: D Vazifeh; H Abdelghaffar; M T Labro
Journal: Antimicrob Agents Chemother Date: 2002-05 Impact factor: 5.191

8. Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999.

Authors: Ian A Critchley; Daniel F Sahm; Clyde Thornsberry; Renée S Blosser-Middleton; Mark E Jones; James A Karlowsky
Journal: Diagn Microbiol Infect Dis Date: 2002-02 Impact factor: 2.803

9. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses.

Authors: F Namour; D H Wessels; M H Pascual; D Reynolds; E Sultan; B Lenfant
Journal: Antimicrob Agents Chemother Date: 2001-01 Impact factor: 5.191

10. Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns.

Authors: Helio S Sader; Ronald N Jones; Juliana B Silva
Journal: Diagn Microbiol Infect Dis Date: 2002-11 Impact factor: 2.803

9 in total

Review 1. Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future.

Authors: Christian Joukhadar; Markus Müller
Journal: Clin Pharmacokinet Date: 2005 Impact factor: 6.447

2. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses.

Authors: Pejman Dehghanyar; Cornelia Bürger; Markus Zeitlinger; Florian Islinger; Florian Kovar; Markus Müller; Charlotte Kloft; Christian Joukhadar
Journal: Antimicrob Agents Chemother Date: 2005-06 Impact factor: 5.191

3. Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and whole-body physiologically based pharmacokinetic modelling.

Authors: Andrea N Edginton; Gertrud Ahr; Stefan Willmann; Heino Stass
Journal: Clin Pharmacokinet Date: 2009 Impact factor: 6.447

Review 4. Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.

Authors: Daniel Gonzalez; Stephan Schmidt; Hartmut Derendorf
Journal: Clin Microbiol Rev Date: 2013-04 Impact factor: 26.132

Review 5. A comprehensive review on the pharmacokinetics of antibiotics in interstitial fluid spaces in humans: implications on dosing and clinical pharmacokinetic monitoring.

Authors: Tony K L Kiang; Urs O Häfeli; Mary H H Ensom
Journal: Clin Pharmacokinet Date: 2014-08 Impact factor: 6.447